R R J Coebergh van den Braak1, L B van Rijssen2, J J van Kleef3, G R Vink4,5, M Berbee6, M I van Berge Henegouwen2, H J Bloemendal7, M J Bruno8, M C Burgmans9, O R C Busch2, P P L O Coene10, V M H Coupé11, J W T Dekker12, C H J van Eijck1, M A G Elferink4, F L G Erdkamp13, W M U van Grevenstein14, J W B de Groot15, N C T van Grieken16, I H J T de Hingh17, M C C M Hulshof18, J N M Ijzermans1, L Kwakkenbos19, V E P P Lemmens4, M Los20, G A Meijer21, I Q Molenaar14, G A P Nieuwenhuijzen17, M E de Noo22, L V van de Poll-Franse23, C J A Punt3, R C Rietbroek24, W W H Roeloffzen25, T Rozema26, J P Ruurda14, J W van Sandick27, A H W Schiphorst28, H Schipper29, P D Siersema30, M Slingerland31, D W Sommeijer32, M C W Spaander8, M A G Sprangers33, H B A C Stockmann34, M Strijker2, G van Tienhoven18, L M Timmermans29, M L R Tjin-A-Ton35, A M T van der Velden36, M J Verhaar37, H M Verkooijen38, W J Vles39, J M P G M de Vos-Geelen40, J W Wilmink3, D D E Zimmerman41, M G H van Oijen3,4, M Koopman5, M G H Besselink2, H W M van Laarhoven3. 1. a Department of Surgery , Erasmus MC University Medical Center , Rotterdam , The Netherlands. 2. b Department of Surgery , Academic Medical Center, Cancer Center Amsterdam , Amsterdam , The Netherlands. 3. c Department of Medical Oncology , Academic Medical Center , Amsterdam , The Netherlands. 4. d Netherlands Comprehensive Cancer Organization , Utrecht , The Netherlands. 5. e Department of Medical Oncology , University Medical Center Utrecht , Utrecht , The Netherlands. 6. f Department of Radiation Oncology , Maastro Clinic , Maastricht , The Netherlands. 7. g Department of Medical Oncology , Meander Medisch Centrum , Amersfoort , The Netherlands. 8. h Department of Gastroenterology and Hepatology , Erasmus MC University Medical Center , Rotterdam , The Netherlands. 9. i Department of Radiology , Leiden University Medical Center , Leiden , The Netherlands. 10. j Department of Surgery , Maasstad Hospital , Rotterdam , The Netherlands. 11. k Department of Epidemiology and Biostatistics , VU University Medical Center , Amsterdam , The Netherlands. 12. l Department of Surgery , Reinier de Graaf Hospital , Delft , The Netherlands. 13. m Department of Medical Oncology , Zuyderland Medisch Centrum , Heerlen , The Netherlands. 14. n Department of Surgery , University Medical Center Utrecht , Utrecht , The Netherlands. 15. o Department of Medical Oncology , Isala, Zwolle , The Netherlands. 16. p Department of Pathology , VU University Medical Center, Cancer Center Amsterdam , Amsterdam , The Netherlands. 17. q Department of Surgery , Catharina Hospital , Eindhoven , The Netherlands. 18. r Department of Radiotherapy , Academic Medical Center, Cancer Center Amsterdam , Amsterdam , The Netherlands. 19. s Living with Hope , Heemstede , The Netherlands. 20. t Department of Medical Oncology , St. Antonius Hospital , Nieuwegein , The Netherlands. 21. u Department of Pathology , Netherlands Cancer Institute , Amsterdam , The Netherlands. 22. v Department of Surgery , Deventer Hospital , Deventer , The Netherlands. 23. w Research Department , Tilburg University , Tilburg , The Netherlands. 24. x Department of Medical Oncology , Rode Kruis Hospital , Beverwijk , The Netherlands. 25. y Department of Medical Oncology , Treant Zorggroep , Hoogeveen , The Netherlands. 26. z Department of Radiotherapy , Instituut Verbeeten , Tilburg , The Netherlands. 27. aa Department of Surgery , Netherlands Cancer Institute - Antoni van Leeuwenhoek , Amsterdam , The Netherlands. 28. ab Department of Surgery , Diakonessenhuis , Utrecht , The Netherlands. 29. ac Stichting voor Patiënten met Kanker aan het Spijsverteringskanaal (SPKS) , Utrecht , The Netherlands. 30. ad Department of Gastroenterology , Radboud University Medical Center , Nijmegen , The Netherlands. 31. ae Department of Medical Oncology , Leiden University Medical Center , Leiden , The Netherlands. 32. af Department of Medical Oncology , Flevoziekenhuis , Almere , The Netherlands. 33. ag Department of Medical Psychology , Academic Medical Center , Amsterdam , The Netherlands. 34. ah Department of Surgery , Kennemer Gasthuis , Haarlem , The Netherlands. 35. ai Department of Medical Oncology , Hospital Rivierenland , Tiel , The Netherlands. 36. aj Department of Medical Oncology , Tergooi Hospital , Hilversum , The Netherlands. 37. ak Department of Medical Oncology , Zuwe Hofpoort Hospital , Woerden , The Netherlands. 38. al Department of Epidemiology , University Medical Center Utrecht , Utrecht , The Netherlands. 39. am Department of Surgery , Ikazia Hospital , Rotterdam , The Netherlands. 40. an Department of Medical Oncology , Maastricht University Medical Center , Maastricht , The Netherlands. 41. ao Department of Surgery , Elisabeth-Tweesteden Hospital , Tilburg , The Netherlands.
Abstract
BACKGROUND: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients. MATERIAL AND METHODS: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future. RESULTS: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing. CONCLUSION: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies can be performed in an efficient, safe, and comprehensive setting.
BACKGROUND: The increasing sub-classification of cancerpatients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancerpatients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancerpatients. MATERIAL AND METHODS: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future. RESULTS: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing. CONCLUSION: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies can be performed in an efficient, safe, and comprehensive setting.
Authors: E Jezerskyte; L M Saadeh; E R C Hagens; M A G Sprangers; L Noteboom; H W M van Laarhoven; W J Eshuis; M I van Berge Henegouwen; S S Gisbertz Journal: World J Surg Date: 2020-03 Impact factor: 3.352
Authors: R Troisi; T Bjørge; M Gissler; T Grotmol; C M Kitahara; S M Myrtveit Saether; A G Ording; C Sköld; H T Sørensen; B Trabert; I Glimelius Journal: J Intern Med Date: 2018-03-25 Impact factor: 8.989
Authors: Anke Richters; Richard P Meijer; Niven Mehra; Joost L Boormans; Antoine G van der Heijden; Michiel S van der Heijden; Lambertus A Kiemeney; Katja K Aben Journal: BMJ Open Date: 2021-05-18 Impact factor: 2.692
Authors: E Jezerskyte; L M Saadeh; E R C Hagens; M A G Sprangers; L Noteboom; H W M van Laarhoven; W J Eshuis; M C C M Hulshof; M I van Berge Henegouwen; S S Gisbertz Journal: J Gastrointest Surg Date: 2020-09-09 Impact factor: 3.452
Authors: Esther N Pijnappel; Willemieke P M Dijksterhuis; Mirjam A G Sprangers; Simone Augustinus; Judith de Vos-Geelen; Ignace H J T de Hingh; Izaak Q Molenaar; Olivier R Busch; Marc G Besselink; Johanna W Wilmink; Hanneke W M van Laarhoven Journal: Support Care Cancer Date: 2022-02-15 Impact factor: 3.359
Authors: H J F Brenkman; E C Gertsen; E Vegt; R van Hillegersberg; M I van Berge Henegouwen; S S Gisbertz; M D P Luyer; G A P Nieuwenhuijzen; J J B van Lanschot; S M Lagarde; W O de Steur; H H Hartgrink; J H M B Stoot; K W E Hulsewe; E J Spillenaar Bilgen; M J van Det; E A Kouwenhoven; D L van der Peet; F Daams; J W van Sandick; N C T van Grieken; J Heisterkamp; B van Etten; J W Haveman; J P Pierie; F Jonker; A Y Thijssen; E J T Belt; P van Duijvendijk; E Wassenaar; H W M van Laarhoven; F J Wessels; N Haj Mohammad; H F van Stel; G W J Frederix; P D Siersema; J P Ruurda Journal: BMC Cancer Date: 2018-04-20 Impact factor: 4.430
Authors: Tom van den Ende; Frank A Abe Nijenhuis; Héctor G van den Boorn; Emil Ter Veer; Maarten C C M Hulshof; Suzanne S Gisbertz; Martijn G H van Oijen; Hanneke W M van Laarhoven Journal: Front Oncol Date: 2019-07-25 Impact factor: 6.244
Authors: I van den Berg; S van de Weerd; J M L Roodhart; G R Vink; R R J Coebergh van den Braak; C R Jimenez; S G Elias; D van Vliet; M Koelink; E Hong; W M U van Grevenstein; M G H van Oijen; R G H Beets-Tan; J H J M van Krieken; J N M IJzermans; J P Medema; M Koopman Journal: BMC Cancer Date: 2020-08-18 Impact factor: 4.430
Authors: Astrid E Slagter; Edwin P M Jansen; Hanneke W M van Laarhoven; Johanna W van Sandick; Nicole C T van Grieken; Karolina Sikorska; Annemieke Cats; Pietje Muller-Timmermans; Maarten C C M Hulshof; Henk Boot; Maartje Los; Laurens V Beerepoot; Frank P J Peters; Geke A P Hospers; Boudewijn van Etten; Henk H Hartgrink; Mark I van Berge Henegouwen; Grard A P Nieuwenhuijzen; Richard van Hillegersberg; Donald L van der Peet; Heike I Grabsch; Marcel Verheij Journal: BMC Cancer Date: 2018-09-10 Impact factor: 4.430
Authors: T M Mackay; F J Smits; A E J Latenstein; A Bogte; B A Bonsing; H Bos; K Bosscha; L A A Brosens; L Hol; O R C Busch; G J Creemers; W L Curvers; M den Dulk; S van Dieren; L M J W van Driel; S Festen; E J M van Geenen; L G van der Geest; D J A de Groot; J W B de Groot; N Haj Mohammad; B C M Haberkorn; J T Haver; E van der Harst; G J M Hemmink; I H de Hingh; C Hoge; M Y V Homs; N C van Huijgevoort; M A J M Jacobs; E D Kerver; M S L Liem; M Los; H Lubbinge; S A C Luelmo; V E de Meijer; L Mekenkamp; I Q Molenaar; M G H van Oijen; G A Patijn; R Quispel; L B van Rijssen; T E H Römkens; H C van Santvoort; J M J Schreinemakers; H Schut; T Seerden; M W J Stommel; A J Ten Tije; N G Venneman; R C Verdonk; J Verheij; F G I van Vilsteren; J de Vos-Geelen; A Vulink; C Wientjes; F Wit; F J Wessels; B Zonderhuis; C H van Werkhoven; J E van Hooft; C H J van Eijck; J W Wilmink; H W M van Laarhoven; M G Besselink Journal: Trials Date: 2020-04-16 Impact factor: 2.279